Scarica l'app Stockscreener
76.29
0.84%
-0.65
Dopo l'orario di chiusura:
76.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics says MYKORZO launch tops expectations as HCM data draws praise - MSN
A Look At Cytokinetics (CYTK) Valuation After A Strong Multi‑Year Share Price Performance - Yahoo Finance
Cytokinetics’s SWOT analysis: biotech stock faces profitability test By Investing.com - Investing.com South Africa
Cytokinetics’s SWOT analysis: biotech stock faces profitability test - Investing.com
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise - TradingView
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $264,915, According to a Recent SEC Filing - marketscreener.com
Cytokinetics to Hold Annual Meeting of Stockholders - The Manila Times
Cytokinetics (CYTK) R&D EVP exercises options and sells 3,500 shares - Stock Titan
CYTK: MYQORZO outperforms launch targets, with robust uptake, expanding access, and strong pipeline progress - TradingView
CYTK Initiated Coverage by Citigroup -- Price Target Set at $99. - GuruFocus
Cytokinetics Inc stock (US2328281044): pipeline updates keep biotech in focus - AD HOC NEWS
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
GABELLI & Co INVESTMENT ADVISERS INC. Sells 23,900 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM - American Heart Association Journals
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 7,500 Shares of Stock - MarketBeat
Cytokinetics president & CEO Blum sells $584,400 in common stock. By Investing.com - Investing.com Nigeria
Cytokinetics president & CEO Blum sells $584,400 in common stock. - Investing.com
Cytokinetics Inc stock (US2328281044): CLIMB muscle biology symposium adds to MYQORZO launch momentu - AD HOC NEWS
Cytokinetics (CYTK) CEO sells 7,500 shares, holds 400,330 - Stock Titan
Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB) - Yahoo Finance
Q2 EPS Estimates for Cytokinetics Raised by HC Wainwright - MarketBeat
1CYTK.MI Stock Price, Quote & Chart | CYTOKINETICS INC (BIT:1CYTK) - ChartMill
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $97 - Moomoo
CYTK Maintained by JP Morgan -- Price Target Raised to $97.00 - GuruFocus
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
Investors Purchase High Volume of Call Options on Cytokinetics (NASDAQ:CYTK) - MarketBeat
JPMorgan Chase & Co. Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - MarketBeat
Growth Investors: Industry Analysts Just Upgraded Their Cytokinetics, Incorporated (NASDAQ:CYTK) Revenue Forecasts By 11% - Yahoo Finance
Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week - Moomoo
Cytokinetics (CYTK) Unveils Positive MYQORZO Data at ESC 2026 Co - GuruFocus
One Bay Area company scored $800 million around its heart drug. Here's another targeting the same condition - The Business Journals
CYTK Maintains by HC Wainwright & Co. -- Price Target Raised to $140 - GuruFocus
Cytokinetics completes $805 million public offering - The Pharma Letter
Cytokinetics presents new data on heart drug aficamten - Investing.com
Cytokinetics presents new data on heart drug aficamten By Investing.com - Investing.com South Africa
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026 - Caledonian Record
Heart drug MYQORZO shows long-term safety as HCM burden detailed - Stock Titan
Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech with 35.91% Potential Upside and Groundbreaking Innovations - DirectorsTalk Interviews
Can Myqorzo drive growth for Cytokinetics amid competition? - MSN
Cytokinetics (NASDAQ: CYTK) prices $760.2M common stock sale at $71 - Stock Titan
Cytokinetics closes $805 million stock offering By Investing.com - Investing.com South Africa
Cytokinetics closes $805 million stock offering - Investing.com
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million - The Manila Times
$805M raised as Cytokinetics sells 11.3M shares at $71 each - Stock Titan
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):